Register for our free email digests:
Oregon Health & Science University
Latest From Protiva Biotherapeutics Inc.
Alnylam Pharmaceuticals, a pioneer in RNA interference ("gene silencing"), has raised $92.7 million in a public offering that was well received by the market. The offered shares were priced at $10.75 per share, a 13% discount to the prevailing price on 13 February, and the company’s stock price fell quickly to around $11.0 on 14 February. However, it quickly rebounded to close on 16 February at $12.59.
A British Columbia court orders AlCana to return thousands of documents it allegedly downloaded from Tekmira’s electronic document management system. The claim arose from Tekmira’s suit against Alnylam and AlCana alleging trade secrets theft.
1953 was an extraordinary year for biology, an annus mirabilis, or wonder year, which offered scientific insights to rival those made by Einstein almost half a century earlier.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.